The HIVEP1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of human A-549 lung epithelial cells with targeted disruption of the HIVEP1 gene. This knockout model is produced using CRISPR/Cas9-mediated gene disruption, generating a heterogeneous pool of cells harboring loss-of-function modifications in the HIVEP1 locus, enabling robust study of gene function without clonal selection artifacts.
The A-549 cell line is a widely characterized model of human lung adenocarcinoma derived from a 58-year-old male, exhibiting epithelial morphology and commonly employed in cancer biology, immunology, and drug discovery research. These cells retain key signaling pathways, including NF-??B and cytokine signaling, making them a relevant system for investigating inflammatory and oncogenic processes.
HIVEP1 (human immunodeficiency virus type I enhancer binding protein 1) encodes a large zinc-finger transcription factor that binds ??B-like enhancer elements, functioning primarily as a transcriptional repressor to modulate NF-??B activity. It directly interacts with NF-??B subunits (p65/p50) and cofactors such as p300, and is regulated by upstream signals from TNF-??, IL-1??, and Toll-like receptor ligands. In the NF-??B pathway, activation of receptors like TLRs recruits adaptors MyD88 and IRAK1, leading to TAK1-mediated phosphorylation of I??B?? and subsequent nuclear translocation of NF-??B. HIVEP1 then competes with NF-??B for ??B motifs, repressing transcription of downstream targets including cytokine genes, chemokines, and other immune response genes. Its activity also intersects with other ZAS family proteins and provides negative feedback control of inflammatory gene expression.
In the A-549 lung adenocarcinoma background, HIVEP1 knockout disrupts this regulatory circuit, leading to altered NF-??B-driven transcription and dysregulated cytokine production. Given the role of NF-??B in cancer cell survival, proliferation, and immune evasion, this model is particularly suited for dissecting the contribution of HIVEP1 to tumor-mediated inflammation and immune microenvironment modulation. It provides a physiologically relevant platform for studying how loss of HIVEP1 impacts cancer cell behavior in response to inflammatory stimuli.
This polyclonal knockout cell population is an ideal tool for investigating NF-??B signaling dynamics using luciferase reporter assays, ChIP-seq analysis of ??B-occupied loci, and RT-qPCR profiling of downstream effectors. Functional consequences can be assessed through cytokine ELISA, western blotting of pathway activation markers, and migration assays to evaluate metastatic potential. It supports drug screening against NF-??B modulators and RNA-seq-based transcriptomic studies to uncover broader regulatory networks. With validated applications in immunology, cancer biology, and inflammatory disease research, these cells enable precise dissection of HIVEP1-mediated transcriptional control. For further details, please contact Ascent Research.
